TABLE 1.
Identifications of mutations conferring resistance to compound-mediated inhibition
| Identifier | Straina | Compoundb | Passagec | Resistanced | Molecular basise |
|---|---|---|---|---|---|
| I | MV-Edm | OX-1 | 4 | >25 | F-N462S |
| II | MV-KS | AS-48 | 6 | >25 | F-N462D |
| III | MV-KS | AS-48 | 6 | 15 | F-A367T |
| IV | MV-KS | AS-48 | 7 | >25 | F-N462D |
| V | MV-KS | AS-48 | 7 | >25 | F-V94M |
| F-N462D | |||||
| VIf | MV-B3-2 | >25 | F-462K |
a
Input strain used for each independent adaptation procedure.
b
Compound used for adaptation (OX-1, 60 μM; AS-48, 15 μM [final concentration]).
c
Passage number at which extensive cytopathic effect was observed in the presence of compound.
d
Resistance (n-fold) to AS-48 of recombinant virions harboring the identified point mutation compared to that of the input strain or an rMV-Edm F-B3-2 (462N) variant.
e
Mutation conferring resistance as determined by transient-inhibition assay and resistance of recombinant virions.
f
Naturally resistant wild-type isolate MVi/lbadan.NIE/97/1 (MV-B3-2; genotype B3-2), assessed for compounds OX-1 and AS-48.